TMO stock: buy or sell?
Updated on:
September 20th, 2019
4
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Should I buy TMO stock?
Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.Currently, Thermo Fisher Scientific stock doesn't match any of these trading strategies, so our recommendation is not to buy.
| Buy setup | Elegible |
|---|---|
| New all-time high | No |
| New 52 week high | No |
| Price crossing up 200d MA | No |
| 100d MA crossing up 200d MA | No |
Is Thermo Fisher Scientific stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.
At Stocks2.com, we detected 11 ratings published for TMO stock in the last 30 days. The general sentiment of these ratings is bullish for TMO stock, with 11 positive ratings.| Date | Analyst / Broker | Previous rating | Current rating |
| 2019-7-25 | Needham & Company LLC | n/a | Buy |
| 2019-7-16 | Needham & Company LLC | Strong-Buy | Buy |
| 2019-5-23 | UBS Group | n/a | Buy |
| 2019-4-16 | Bank of America | Buy | Buy |
| 2019-3-26 | Robert W. Baird | Outperform | Outperform |
| 2019-3-26 | BTIG Research | n/a | Buy |
| 2019-3-25 | UBS Group | n/a | Buy |
| 2019-3-22 | Deutsche Bank | n/a | Buy |
| 2019-3-18 | Barclays | Overweight | Overweight |
| 2019-1-31 | BTIG Research | n/a | Buy |
| 2019-1-3 | Barclays | Overweight | Overweight |
TMO stock analysis
Daily outlook
Shares of Thermo Fisher Scientific gained a tiny 0.37% and closed at $296.33.
Shares of Thermo Fisher Scientific gained a tiny 0.37% and closed at $296.33. TMO is soaring again after a 2.29% correction from its last top on September 13th at $297.85. Since price and SMA100d lines crossed up on August 29th, TMO climbed $20.45 (7.41%). On July, TMO hit a new all time high, pushing higher than on July tops. Check different trading setups that use ATHs as triggers.
Weekly outlook
Thermo Fisher Scientific stayed steady a lame -0.38% this week. Late August TMO rocketed a super good 6.17% in just one week.
TMO shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $266.32 early August. Previous top ($305.26) will play as a resistance in possible new gains. Not so far away is the last all-time high Thermo Fisher Scientific marked early July. Early January TMO price bounced up over the SMA of 40 weeks that acted as support stopping new slides. Since SMA10d and SMA20w crossed up by mid February, TMO price climbed $44.35 per share (17.60%).
TMO stock price history
TMO stock went public on March 17th, 1980 with a price of $1.761. Since then, TMO stock surged a 16,736.90%, with an average of 429.20% per year. If you had invested $1,000 in TMO stock in 1980, it would worth $167,369.00 today.
1: Adjusted price after possible price splits or reverse-splits.
TMO stock historical price chart
TMO stock reached all-time highs on July with a price of $305.26.
TMO stock price target is $302.60
Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 11 price targets for TMO stock:| Date | Analyst / Broker | Action | Previous target | Current target | Diff |
| 2019-7-25 | Needham & Company LLC | Raises Target | $315.00 | $321.00 | 1.9% |
| 2019-7-16 | Needham & Company LLC | Downgrades | n/a | $315.00 | - |
| 2019-5-23 | UBS Group | Raises Target | n/a | $320.00 | - |
| 2019-4-16 | Bank of America | Reiterates | $285.00 | $300.00 | 5.3% |
| 2019-3-26 | Robert W. Baird | Raises Target | $270.00 | $288.00 | 6.7% |
| 2019-3-26 | BTIG Research | Raises Target | n/a | $310.00 | - |
| 2019-3-25 | UBS Group | Raises Target | n/a | $305.00 | - |
| 2019-3-22 | Deutsche Bank | Raises Target | $275.00 | $300.00 | 9.1% |
| 2019-3-18 | Barclays | Raises Target | $295.00 | $300.00 | 1.7% |
| 2019-1-31 | BTIG Research | Raises Target | n/a | $290.00 | - |
| 2019-1-3 | Barclays | Raises Target | $275.00 | $280.00 | 1.8% |
| (in average) | $285.80 | $302.60 | 6.0% |
Financials and fundamental analysis
Earnings date and Earnings per Share
Since April, when Thermo Fisher Scientific presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.| Quarter | Reporting date | Estimated EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| 2017-Q2 | - | n/a | 1.63 | n/a |
| 2017-Q3 | 2017-10-25 | 2.25 | 2.31 | 2.7% |
| 2017-Q4 | 2018-01-31 | 2.66 | 2.79 | 4.9% |
| 2018-Q1 | 2018-04-25 | 2.42 | 2.5 | 3.3% |
| 2018-Q2 | 2018-07-25 | 2.63 | 2.75 | 4.6% |
| 2018-Q3 | 2018-10-24 | 2.55 | 2.62 | 2.7% |
| 2018-Q4 | 2019-01-30 | 3.19 | 3.25 | 1.9% |
| 2019-Q1 | 2019-04-23 | 2.74 | n/a | n/a |
| 2019-Q2 | - | n/a | n/a | n/a |
| 2019-Q3 | - | n/a | n/a | n/a |
Annual financial results
Compared to 2017, last anual sales report draw an exceptional gain of 16.45% to $24,358.00 M dollars. When comparing 2018 vs 2017, in contrast, profit margin (that is, the net income divided by revenues) gained a 1.42% to 12.06%. To have an up to date picture of the financial situation of Thermo Fisher Scientific, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Thermo Fisher Scientific TTM sales up to March 2019 were $24,630.00 and earnings were $3,174.00 M dollars. When comparing this TTM figures with the last reported annuality, we can review Thermo Fisher Scientific business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, appreciated a tiny 1.12%. In the same way, profit margin (net income/sales) remained stable at 12.06%.| Year | Sales | YoY | Income/(margin) | YoY |
|---|---|---|---|---|
| 2013 | $13,090 M | - | $1,280 M9.8% | - |
| 2014 | $16,890 M | 29.03% | $1,894 M11.2% | 48.00% |
| 2015 | $16,965 M | 0.45% | $1,975 M11.6% | 4.28% |
| 2016 | $18,274 M | 7.71% | $2,022 M11.1% | 2.35% |
| 2017 | $20,918 M | 14.47% | $2,225 M10.6% | 10.05% |
| 2018 | $24,358 M | 16.45% | $2,938 M12.1% | 32.04% |
| TTM | $24,630 M | 1.12% | $3,174 M12.9% | 8.03% |
Quarterly financial results
Thermo Fisher Scientific posted $6,125.00 million in revenues for 2019-Q1, a -5.87% less compared to previous quarter. Reported quarter income marked $815.00 M with a profit margin of 13.31%. Profit margin stayed constant a -0.49% compared to previous quarter when profit margin was 13.80%. When comparing revenues to same quarter last year, Thermo Fisher Scientific sales marked a fine increase and stepped up a 4.65%.| Quarter | Sales1 | QoQ2 | Income1/(margin) | QoQ2 |
|---|---|---|---|---|
| 2017-Q2 | $4,990 M | - | $612 M12.3% | - |
| 2017-Q3 | $5,120 M | 2.61% | $534 M10.4% | -12.79% |
| 2017-Q4 | $6,047 M | 18.11% | $528 M8.7% | -1.11% |
| 2018-Q1 | $5,853 M | -3.21% | $579 M9.9% | 9.66% |
| 2018-Q2 | $6,078 M | 3.84% | $752 M12.4% | 29.88% |
| 2018-Q3 | $5,920 M | -2.60% | $709 M12.0% | -5.72% |
| 2018-Q4 | $6,507 M | 9.92% | $898 M13.8% | 26.66% |
| 2019-Q1 | $6,125 M | -5.87% | $815 M13.3% | -9.24% |
Thermo Fisher Scientific ownership
When you are planning to invest in a stock, it's worth to review its ownership structure.Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Thermo Fisher Scientific, 0.19% of all outstanding shares are owned by its staff.
Bearish positions for TMO stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Thermo Fisher Scientific:
| TMO | A | BAX | BDX | BIO | |
|---|---|---|---|---|---|
| Market cap | $118.7 B | $24.2 B | $44.6 B | $68.5 B | $8.4 B |
| Total shares | 400.5 M | 309.5 M | 510.6 M | 270.0 M | 24.7 M |
| Float shares | 399.4 M | 308.4 M | 509.6 M | 269.1 M | 21.3 M |
| - Institutional holdings (%) | 90.7% | 88.2% | 88.2% | 87.5% | 78.0% |
| - Insider holdings (%) | 0.2% | 0.4% | 0.1% | 0.3% | 14.6% |
| Shares in short selling | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
TMO summary
| Friday, September 20th, 2019 | |
|---|---|
| Open | $297.29 |
| Close | $296.33 |
| Day range | $295.56 - $299.08 |
| Previous close | $295.25 |
| Session gain | 0.37% |
| Average true range | $5.14 |
| 50d mov avg | $284.03 |
| 100d mov avg | $282.18 |
| 200d mov avg | $265.99 |
| Daily pattern | lb01a |
| Weekly pattern | lb03a |
Thermo Fisher Scientific performance
Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Agilent Technologies, Baxter International, Becton, Dickinson and, Bio-Rad Laboratories, Danaher, Harvard Bioscience, Intuitive Surgical, PerkinElmer, Teleflex and Waters as the bechmarking frame for Thermo Fisher Scientific stock.| Stock | 3m | 6m | 12m |
|---|---|---|---|
| TMOThermo Fisher Sci... | 0.70% | 12.47% | 22.04% |
| AAgilent Technolog... | 6.68% | -0.75% | 11.37% |
| BAXBaxter Internatio... | 6.33% | 13.77% | 14.19% |
| BDXBecton, Dickinson... | 2.85% | 6.27% | -1.81% |
| BIOBio-Rad Laborator... | 11.54% | 11.17% | 13.82% |
| DHRDanaher | 1.96% | 13.15% | 36.18% |
| HBIOHarvard Bioscienc... | 63.46% | -13.49% | -34.62% |
| ISRGIntuitive Surgica... | 0.75% | -5.36% | -4.60% |
| PKIPerkinElmer | -9.16% | -7.50% | -10.13% |
| TFXTeleflex | 2.18% | 13.50% | 27.25% |
| WATWaters | 7.47% | -6.79% | 16.24% |
Thermo Fisher Scientific competitors
One check before trading any stock is to have a look a list of its competitors, in this case for Thermo Fisher Scientific. We chose 10 companies as Thermo Fisher Scientific competitors as they are in the same industry or have similar market objectives.- Agilent Technologies (A)
- Baxter International (BAX)
- Becton, Dickinson and (BDX)
- Bio-Rad Laboratories (BIO)
- Danaher (DHR)
- Harvard Bioscience (HBIO)
- Intuitive Surgical (ISRG)
- PerkinElmer (PKI)
- Teleflex (TFX)
- Waters (WAT)
Latest TMO stock news
- InvestorPlace3 Big Stock Charts for Friday: Thermo Fisher Scientific, Intuit and Intercontinental ExchangeJune 22, 2018